menu
    • menu
    [{"orgOrder":0,"company":"Candid Therapeutics","sponsor":"Venrock Healthcare Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Financing","leadProduct":"CND106","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Candid Therapeutics","amount2":0.37,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Candid Therapeutics \/ Venrock Healthcare Capital Partners","highestDevelopmentStatusID":"12","companyTruncated":"Candid Therapeutics \/ Venrock Healthcare Capital Partners"},{"orgOrder":0,"company":"Candid Therapeutics","sponsor":"EpimAb Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Antibody","moa":"","graph1":null,"graph2":null,"graph3":"Candid Therapeutics","amount2":1,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"","sponsorNew":"Candid Therapeutics \/ Candid Therapeutics","highestDevelopmentStatusID":null,"companyTruncated":"Candid Therapeutics \/ Candid Therapeutics"},{"orgOrder":0,"company":"Candid Therapeutics","sponsor":"Nona Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Antibody","moa":"","graph1":null,"graph2":null,"graph3":"Candid Therapeutics","amount2":0.32000000000000001,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"","sponsorNew":"Candid Therapeutics \/ Candid Therapeutics","highestDevelopmentStatusID":null,"companyTruncated":"Candid Therapeutics \/ Candid Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Candid Therapeutics

    Menu

    Candid Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Candid Therapeutics

                            U.S.A arrow
                            Pharmatech Expo 2025
                            Not Confirmed

                            Candid Therapeutics

                            U.S.A arrow
                            Pharmatech Expo 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody

                            Therapeutic Area : Immunology

                            Study Phase : Discovery

                            Recipient : EpimAb Biotherapeutics

                            Deal Size : $1,000.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Candid, EpimAb Collaborate on T-Cell Engagers for Autoimmune Disease Treatments

                            Details : The companies have entered a strategic research collaboration to discover and develop novel T-cell Engager program candidates for various autoimmune indications.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 16, 2024

                            Lead Product(s) : Antibody

                            Therapeutic Area : Immunology

                            Highest Development Status : Discovery

                            Recipient : EpimAb Biotherapeutics

                            Deal Size : $1,000.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Candid Therapeutics

                            U.S.A arrow
                            Pharmatech Expo 2025
                            Not Confirmed

                            Candid Therapeutics

                            U.S.A arrow
                            Pharmatech Expo 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody

                            Therapeutic Area : Immunology

                            Study Phase : Discovery Platform

                            Recipient : Nona Biosciences

                            Deal Size : $320.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Nona Biosciences, Candid Collaborate on Next-Gen T-Cell Engager Discovery Projects

                            Details : Nona's collaboration with Candid aims to advance the discovery of next-generation TCEs (T-cell engagers) focused on treating autoimmune diseases.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 16, 2024

                            Lead Product(s) : Antibody

                            Therapeutic Area : Immunology

                            Highest Development Status : Discovery Platform

                            Recipient : Nona Biosciences

                            Deal Size : $320.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Candid Therapeutics

                            U.S.A arrow
                            Pharmatech Expo 2025
                            Not Confirmed

                            Candid Therapeutics

                            U.S.A arrow
                            Pharmatech Expo 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CND106

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Venrock Healthcare Capital Partners

                            Deal Size : $370.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Candid Therapeutics Raises $370M to Evaluate Autoimmune Therapies Clinically

                            Details : CND106 is a BCMAxCD3 bispecific antibody designed to target and eliminate later stage B-cells which are responsible for producing harmful autoantibodies.

                            Brand Name : CND106

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 09, 2024

                            Lead Product(s) : CND106

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Venrock Healthcare Capital Partners

                            Deal Size : $370.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth